Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5637 |
Name | pancreatic adenosquamous carcinoma |
Definition | A pancreatic ductal carcinoma that derives_from squamous cells and gland-like cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic adenosquamous carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04116073 | Phase II | Retifanlimab | INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic Cancer | Recruiting | USA | 0 |
NCT04229004 | Phase III | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel | A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT04581343 | Phase I | Canakinumab + Gemcitabine + Nab-paclitaxel + Spartalizumab | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients (PanCAN-SR1) | Active, not recruiting | USA | 0 |
NCT04858334 | Phase II | Olaparib | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Recruiting | USA | ISR | 0 |
NCT04896073 | Phase II | Minnelide | A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) | Recruiting | USA | 0 |
NCT05209074 | Phase I | Fluorouracil + Irinotecan + Ivosidenib + Leucovorin + Oxaliplatin | Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT05216120 | Phase II | Pemigatinib | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | Withdrawn | USA | 0 |
NCT05417386 | Phase I | Fluorouracil + Irinotecan + Leucovorin + NIS793 + Oxaliplatin Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | FOLFIRINOX + NIS793 in Pancreatic Cancer | Terminated | USA | 0 |
NCT05419479 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin AB154 + Sotigalimab + Zimberelimab | Switch Maintenance in Pancreatic | Recruiting | USA | 0 |
NCT05440942 | Phase I | Retifanlimab + Ruxolitinib + Trametinib | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT05988918 | Phase II | CEP-11981 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | Recruiting | USA | 0 |